

## Special Issue

# Hematologic Malignancies and Related Disorders: Challenges from Diagnosis to Treatment

### Message from the Guest Editors

Hematologic malignancies represent a constantly changing landscape with promising diagnostic and treatment modalities. Emerging challenges in the field involve not only new treatments and appropriate patient selection but also unprecedented worldwide changes, such as COVID-19. Therefore, this Special Issue aims to highlight basic, translational, and clinical research in the field, gathering both original research and review articles. We welcome physicians and scientists to share their valuable research with us.

---

### Guest Editors

Dr. Ioanna Sakellari

Hematology Department—BMT Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece

Dr. Eleni Gavriilaki

Second Propedeutic Department of Internal Medicine, Hippocraton Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece

---

### Deadline for manuscript submissions

30 September 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/204775](https://mdpi.com/si/204775)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
cancers@mdpi.com

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)